Trinity Biotech Announces Quarter 3 Results Revenues Increase 25%
DUBLIN, IRELAND, Oct 27, 2005 (MARKET WIRE via COMTEX) -- Trinity Biotech plc (NASDAQ: TRIB) (ISE:TRIB.I), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2005. Revenues in the quarter increased 25.1% to US$26.9 million compared to US$21.5 million in the same period last year. Revenues for the year to date by key product area were as follows :
2004 2005
Q1 - Q3 Q1 - Q3
US$000 US$000 % Increase
Infectious Disease 25,442 33,130 30.2
Coagulation 19,911 21,490 7.9
POC 7,221 9,467 31.1
Clinical Chemistry 5,361 6,731 25.6
Total 57,935 70,818 22.2
|